This double-blind , parallel-group , single-center study enrolled and randomized 36 healthy subjects ( 22 men , 14 women ) to receive subcutaneous doses of teduglutide 4 mg or placebo ( 2:1 ratio ; 23:13 ) once daily on Days 1 through 10 in the morning .